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Background
• LB is a 6-year old with pancreatic insufficient CF
• Delivered at 35 weeks EGA and diagnosed with meconium ileus
– Segmental resection of 7 cm of the distal ileum and ileostomy
– Ileostomy take-down at 8 weeks of age

• Intermittent use of TPN but discharged from NICU at 3 ½ months of age
on full oral feedings
• Intermittent gastrointestinal issues and poor growth early in life

Ivacaftor/Lumacaftor Therapy
• Medications
– Pancreatic enzyme replacement therapy (16,000 lipase units/capsule; 4
capsules with meals and snacks [3,200 lipase units/kg/meal])
– H2 blocker
– Fat-soluble vitamin supplementation
– Bronchodilator therapy prior to assisted airway clearance BID
– 7% saline BID
– Dornase alfa QD

• BMI at the 63rd percentile
• FEV1 was 95% of predicted
• Ivacaftor/Lumacaftor (100mg/125mg), 2 tablets BID, started

• Day 2: increased cough; increased number of stools with steatorrhea,
abdominal distension, mild discomfort
• Day 5: cough resolved; number of stools, steatorrhea, and GI symptoms
did not improve
• Day 14: bowel prep with polyethylene glycol without improvement
• Day 21: ivacaftor/lumacaftor (100mg/125mg) dose changed to 1
tablet BID; improvement in symptoms but continued increased stools and
steatorrhea
•

Day 28: PERT increased to 5 capsules with meals (4210 lipase units/kg/meal)
without improvement

• Day 56: H2 blocker changed to PPI without change in symptoms
• Stools studies sent for comprehensive infectious diarrhea panel
– Shiga toxin and Campylobacter antigen negative
– Giardia, Cryptococcus, and Entamoeba tests negative
– Salmonella and Shigella cultures negative

• Day 70: ivacaftor/lumacaftor therapy discontinued following long
conversation with the family

Discontinuation of Therapy
• Stooling pattern returned to normal within 48 hours of discontinuation of
ivacaftor/lumacaftor therapy
– Normal number of stools
– Complete resolution of steatorrhea

• No change in normal stooling pattern after return to routine PERT dosing
and H2 blocker

Discussion Points
• What are the physiologic effects of CFTR modulators on the GI system?
• Is there something about patients with a history of MI and small bowel
resection that places them at increased risk for poor gastrointestinal
tolerance of CFTR modulators?
• What are therapeutic options for this child moving forward?

Effects of CFTR Modulators on the GI
Track
•
•
•
•
•

Improved HCO3- secretion and intestinal pH1,2
Fecal elastase increases3,4
Discontinuation of PERT (2 case reports)
Biliary function?
Alteration in GI microbiome?
1.
2.
3.
4.
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Meconium Ileus, Bowel Resection, and
CFTR Modulators
• The Theory
– MI with resection resulted in “anatomic short gut”
– CF resulted in abnormal luminal contents and decreased motility
(“physiologically slow gut”)
• “anatomic short gut” + “physiologically slow gut” = “functionally normal gut”

– Treatment with ivacaftor/lumacaftor resulted in normalized luminal contents and
improved motility (“physiologically normal gut”)
•

“anatomic short gut” + “physiologically normal gut” = “functionally short gut
syndrome”

Where do we go from here?
• Reintroduce ivacaftor/lumacaftor with motility or biliary modulating
agent
• Reintroduce ivacaftor/lumacaftor or other modulator when GI effects
are more acceptable
• Other?
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